Trial intelligence / Profile preview

Ambrisentan in pediatric pulmonary arterial hypertension

RBR-8vvwj8Phase 2Suspended

Sponsor
GSK
Start
Jan 2011
Modality
Small Molecules
Countries
1
01

Overview

Phase 2 trial of ambrisentan in pulmonary arterial hypertension (PAH) (2 arms), sponsored by GSK. Started Jan 2011; status: suspended.

02

Drugs

ambrisentan
03

Conditions

pulmonary arterial hypertension (PAH)

Beyond the preview

Go deeper on RBR-8vvwj8.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on RBR-8vvwj8.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call